iCAD, Inc. (ICAD)
Market Cap | 42.17M |
Revenue (ttm) | 22.21M |
Net Income (ttm) | -10.00M |
Shares Out | 26.35M |
EPS (ttm) | -0.39 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 73,944 |
Open | 1.600 |
Previous Close | 1.600 |
Day's Range | 1.530 - 1.660 |
52-Week Range | 1.050 - 3.970 |
Beta | 1.36 |
Analysts | Strong Buy |
Price Target | 4.00 (+148.45%) |
Earnings Date | Mar 12, 2024 |
About ICAD
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a ma... [Read more]
Financial Performance
In 2022, iCAD, Inc.'s revenue was $27.94 million, a decrease of -16.93% compared to the previous year's $33.64 million. Losses were -$13.66 million, 21.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ICAD stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 148.45% from the latest price.
News
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect canc...
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)
Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectives Dr. Hricak offers extensive experience in radi...
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect canc...
iCAD's AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence...
iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman's one to two-year risk for breast cancer iCAD unveils...
iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health...
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health...
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast hea...
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
Xoft's eBx System can now be offered to more clinics and cancer patients world-wide through Elekta's extensive sales channels Xoft's eBx System can now be offered to more clinics and cancer patients w...
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada...
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial ...
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will relea...
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation's Largest Radiology Practice
Agreement positions iCAD as Radiology Partners' breast AI provider, expanding potential for iCAD's technology to reach millions of women in the U.S. Agreement positions iCAD as Radiology Partners' bre...
iCAD's “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD's Breast AI Suite helps her detect the breast cancers radiologists fear most Cleveland Clinic breast radiologist, Laura Dean, M...
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting
Company's ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities Company's ROI Tool offers preview of business value the ProFound Breast AI ...
iCAD's ProFound AI Breast Suite Wins U.S. General Services Administration's AI Healthcare Challenge Award
Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomes Company presented portfolio of breast ...
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
NASHUA, N.H., May 15, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial a...
ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer ProFound AI Risk offered higher accura...
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
Strategy focused on profitability by end of 2024, using current cash on hand
iCAD's Breast AI Suite Empowers Customers to Lead the Way in Support of FDA's National Breast Density Reporting Standard
iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Confe...
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business line Company is exploring strategic options for its Therapy business line
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists' Efficiency and Accuracy
Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023 Company's Breast AI Suite of deep-learning breast cancer detectio...
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
Daniel Shea appointed as interim Chief Financial Officer
iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar
Solis Mammography's Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of ProFound AI Solis Mammography's Chief Medical Offi...